2 months ago
APLS
AnalystsEliana MerleEliana Merle's Stock Forecasts
AnalystsEliana Merle
Sectors:
Industries:
Analyst Ranking
Top 20%
#901 out of 4555 analysts
Average Return
+9.8%
Win Rate
43%17 out of 40
Risk vs Reward
Poor
Good
Eliana Merle's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +237.97% | $11.01 | $37.21 | 2022-08-01 - 2023-05-03 | Strong Buy |
Cymabay Therapeutics IncCBAY | +213.84% | $1.59 | $4.99 | 2020-03-12 - 2021-03-12 | Strong Buy |
Cymabay Therapeutics IncCBAY | +166.61% | $12.07 | $32.18 | 2023-08-13 - 2024-02-14 | Strong Buy |
Kadmon Holdings IncKDMN | +148.04% | $3.83 | $9.50 | 2021-05-20 - 2021-11-09 | Strong Buy |
Cymabay Therapeutics IncCBAY | +116.99% | $14.83 | $32.18 | 2023-09-25 - 2024-02-14 | Strong Buy |
Eliana Merle Analyst Color
Get additional color on Eliana Merle's coverage of popular stocks
7 months ago
CBAY
8 months ago
APLS
2 years ago
MRNA
Eliana Merle's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Kodiak Sciences IncKOD | 3 | Hold | $5.00 | +48.81% | Maintains | 16 days ago |
Terns Pharmaceuticals IncTERN | 2 | Strong Buy | $18.00 | +294.74% | Maintains | 24 days ago |
Biontech SeBNTX | 3 | Hold | $101.00 | +16.35% | Maintains | 24 days ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $410.00 | +93.36% | Maintains | a month ago |
Akero Therapeutics IncAKRO | 3 | Strong Buy | $42.00 | +102.31% | Maintains | 2 months ago |
Apellis Pharmaceuticals IncAPLS | 4 | Strong Buy | $89.00 | +87.25% | Maintains | 2 months ago |
Rapt Therapeutics IncRAPT | 1 | Hold | $10.00 | +25.79% | Downgrades | 2 months ago |
Cymabay Therapeutics IncCBAY | 5 | Hold | $32.50 | +0.06% | Downgrades | 2 months ago |
Revolution Medicines IncRVMD | 1 | Strong Buy | $40.00 | +14.55% | Initiates Coverage On | 4 months ago |
Anaptysbio IncANAB | 3 | Hold | $21.00 | +5.69% | Maintains | 6 months ago |
89bio IncETNB | 2 | Strong Buy | $25.00 | +175.33% | Maintains | 6 months ago |
Moderna IncMRNA | 2 | Strong Buy | $191.00 | +88.34% | Upgrades | 10 months ago |
Uniqure NvQURE | 4 | Strong Buy | $42.00 | +799.36% | Maintains | a year ago |
Iveric Bio IncISEE | 2 | Hold | $40.00 | +0.13% | Downgrades | a year ago |
Curevac NvCVAC | 1 | Strong Buy | $18.00 | N/A | Upgrades | a year ago |
Gossamer Bio IncGOSS | 2 | Strong Buy | $8.00 | N/A | Maintains | a year ago |
Monte Rosa Therapeutics IncGLUE | 1 | Strong Buy | $22.00 | N/A | Initiates Coverage On | 2 years ago |
Regenxbio IncRGNX | 1 | Strong Buy | $47.00 | N/A | Maintains | 2 years ago |
Kadmon Holdings IncKDMN | 1 | Strong Buy | $9.00 | N/A | Initiates Coverage On | 3 years ago |
Amicus Therapeutics IncFOLD | 2 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 3 years ago |
Kymera Therapeutics IncKYMR | 1 | Strong Buy | $80.00 | N/A | Initiates Coverage On | 3 years ago |
Zentalis Pharmaceuticals IncZNTL | 2 | Strong Buy | $91.00 | N/A | Initiates Coverage On | 3 years ago |
Arvinas IncARVN | 2 | Strong Buy | $123.00 | N/A | Initiates Coverage On | 3 years ago |
Bridgebio Pharma IncBBIO | 1 | Strong Buy | $80.00 | N/A | Initiates Coverage On | 3 years ago |
Galapagos NvGLPG | 2 | Hold | $134.00 | N/A | Maintains | 4 years ago |
Alexion Pharmaceuticals IncALXN | 1 | Hold | $121.00 | N/A | Initiates Coverage On | 4 years ago |
Cartesian Therapeutics IncRNAC | 1 | Strong Buy | $10.00 | N/A | Initiates Coverage On | 4 years ago |
Tesaro IncTSRO | 1 | Strong Buy | $68.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.